Mikael Simons, MD, a neurologist and researcher at Technical University Munich and the Centre for Neurodegenerative Diseases in Munich, Germany is the winner of the 2024 Barancik Prize for Innovation ...

Symptoms may improve or disappear during remission. Approximately 85% of people receive a diagnosis of RRMS at first, according to the National MS Society. SPMS can follow an initial RRMS diagnosis.

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

A sensation of numbness or pins and needles is a common symptom of MS. According to the National Multiple Sclerosis Society, there are currently no available treatments to relieve the numbness or ...

Symptoms that steadily get worse from the ... However, according to the National MS Society, it is still too early to show the effects of newer disease-modifying therapies. It’s possible that ...

However, a leaked Jan. 14 letter from Woodhouse Nepinak to Blackstock, executive director of the First Nations Child and Family Caring Society, shows the national leader seemingly stepping back ...

Background Multiple Sclerosis is a disease of the central nervous system involving a variety of debilitating physical, sensory, cognitive and emotional symptoms. This literature review evaluated ...

By Christy Piña Associate Editor The National Society of Film Critics has named Nickel Boys its best picture of 2024. The film also received runner-up recognition for Aunjanue Ellis-Taylor as the ...

On Sunday, February 25, 2024, Rocco will walk alongside his family, friends, and those who support Team Rocco in an effort to raise $100K towards the National Multiple Sclerosis Society and to take ...

Objective: The aim of this analysis is to describe the characteristics of pediatric patients with multiple sclerosis who started their treatment with disease-modifying drugs in 2013–2020, with data ...